Biotechnology Rare Disease Law In Ukraine.
1. Introduction
Biotechnology and rare disease law in Ukraine is a developing area of healthcare, pharmaceutical regulation, medical genetics, biotechnology research, human rights and public health governance.
Rare diseases are also known as orphan diseases. They include uncommon genetic, inherited, metabolic, neurological, immunological and congenital conditions. Examples include:
Spinal muscular atrophy (SMA).
Cystic fibrosis.
Gaucher disease.
Phenylketonuria (PKU).
Haemophilia.
Rare inherited metabolic disorders.
Severe combined immunodeficiency (SCID).
Ukraine has established a legal framework to protect people suffering from rare diseases. This framework addresses diagnosis, prevention, treatment, access to medicines, specialised dietary products, medical information and government responsibility.
An important feature of Ukrainian law is that rare-disease patients have a statutory entitlement to continuous and free provision of necessary medicines and relevant special dietary products, subject to the applicable legal procedures and approved lists.
The principal legislation is the Law of Ukraine No. 1213-VII of 15 April 2014, which introduced special provisions concerning the prevention and treatment of rare (orphan) diseases.
2. Legal definition of rare diseases
Under Ukrainian healthcare legislation, a rare (orphan) disease is generally a disease that:
Threatens a person's life or is chronically progressive.
Reduces life expectancy or causes disability.
Has a prevalence of no more than one case per 2,000 people.
This definition is significant because it establishes a legal basis for identifying patients who require specialised medical assistance and public healthcare intervention.
The definition also connects biotechnology with public health because many rare diseases are diagnosed through genetic sequencing, molecular testing, biochemical screening and other advanced diagnostic methods.
Legal authority: Article 53-1 of the Law of Ukraine on the Fundamentals of Health Legislation.
від 19.11.1992 № 2801-XII+1
3. Constitutional foundation
The Ukrainian Constitution provides the foundation for rare-disease protection.
Article 49 – Right to healthcare
Article 49 establishes the constitutional framework for healthcare protection and medical assistance. It provides for free medical care in state and communal healthcare institutions.
Article 24 – Equality before the law
People suffering from rare diseases should not face unjustified discrimination because their medical conditions are uncommon, expensive to treat or genetically inherited.
Article 28 – Human dignity
Medical research, genetic testing and experimental treatment must respect human dignity and bodily integrity.
Article 32 – Privacy
Genetic information, medical histories and information concerning inherited conditions require appropriate protection against unlawful collection, disclosure or use.
These constitutional guarantees should be read together with the statutory protections for rare-disease patients.
4. Principal legislation governing rare diseases
Ukraine's rare-disease framework consists of several laws, government resolutions and Ministry of Health regulations.
| Legislation | Legal significance |
|---|---|
| Law No. 1213-VII of 15 April 2014 | Introduced specific rare-disease protections |
| Law No. 2801-XII of 19 November 1992 | Fundamentals of Health Legislation |
| Cabinet Resolution No. 160 of 31 March 2015 | Free provision of medicines and special dietary products |
| Ministry of Health Order No. 778 of 27 October 2014 | List of rare (orphan) diseases |
| Cabinet Resolution No. 377-r of 28 April 2021 | Development strategy for rare-disease medical care, 2021–2026 |
| Cabinet Resolution No. 1235-r of 11 October 2021 | Implementation plan for the strategy |
| Ministry of Health Order No. 1620 of 7 September 2022 | Network of rare-disease reference centres |
| Ministry of Health Order No. 60 of 15 January 2026 | Updated rare-disease reference directory |
The central statutory provision is Article 53-1 of the Law on the Fundamentals of Health Legislation.
Законодавство України+2
5. Article 53-1: Prevention and treatment of rare diseases
Article 53-1 establishes three important state responsibilities.
A. Prevention
The government must establish appropriate preventive measures for rare diseases.
These measures include:
Genetic counselling.
Early diagnosis.
Newborn screening.
Identification of hereditary diseases.
Public health education.
Medical-genetic assessment.
B. Organisation of medical treatment
The Ministry of Health must establish the relevant disease lists and procedures for organising medical assistance.
This is important because patients with uncommon diseases frequently require specialised medical facilities, genetic laboratories and multidisciplinary treatment.
C. Free and continuous treatment
The law provides that people suffering from rare diseases must receive the medicines and appropriate special dietary products necessary for treatment continuously and free of charge, under the prescribed legal arrangements.
This provision creates a particularly important legal basis for claims against public authorities when eligible patients are deprived of necessary treatment.
від 19.11.1992 № 2801-XII+1
6. Government Resolution No. 160 of 2015: Access to medicines
The Cabinet of Ministers adopted Resolution No. 160 on 31 March 2015.
It establishes the procedure for providing medicines and special dietary products to people suffering from rare diseases.
Its principal features are:
Medicines are supplied according to medical indications.
Healthcare institutions establish commissions to decide whether a patient requires provision, continuation or discontinuation of treatment.
The patient must be informed of the decision.
Written consent is required under the applicable procedure.
Medicines are provided through appropriate healthcare institutions.
The Ministry of Health supervises the provision system.
The resolution was amended in 2020 and 2025. The 2025 amendment is particularly important because it revised the decision-making arrangements, including the role of healthcare-institution commissions.
The procedure covers funding from state budgets, local budgets and other legally permitted sources, including humanitarian assistance.
«Дебет-Кредит» - Нормативні документи
Legal significance: A patient should not be denied access merely because a local administrative authority has failed to organise its internal procedures correctly. The legality of the authority's conduct must be assessed against its statutory responsibilities.
7. Biotechnology and genetic diagnosis
Biotechnology plays a central role in diagnosing rare diseases.
Modern diagnostic techniques include:
DNA sequencing.
Whole-genome sequencing.
Whole-exome sequencing.
Polymerase chain reaction (PCR).
Molecular genetic testing.
Chromosomal analysis.
Biochemical screening.
Next-generation sequencing.
For example, spinal muscular atrophy is associated with alterations involving the SMN1 gene. Genetic testing can assist in confirming the diagnosis and determining the appropriate treatment pathway.
Similarly, molecular testing can identify inherited metabolic conditions, including certain forms of Gaucher disease and phenylketonuria.
Legal issues concerning genetic diagnosis
Ukrainian law must address several important questions:
Informed consent: Patients or their legal representatives must receive appropriate information before genetic testing.
Genetic privacy: Genetic information must be protected from unauthorised disclosure.
Accuracy: Laboratories must maintain appropriate standards of diagnostic reliability.
Clinical responsibility: Healthcare professionals must interpret genetic results in accordance with appropriate medical standards.
Discrimination: Genetic information should not become an unjustified basis for unequal treatment.
The legal framework includes healthcare legislation and the Law of Ukraine on Personal Data Protection.
8. Newborn screening and early diagnosis
Newborn screening is one of the most important applications of biotechnology in rare-disease prevention.
Ukraine expanded its newborn screening programme from 2022 to cover 21 rare inherited and congenital diseases.
The programme uses laboratory testing, including biochemical and molecular methods, to identify potentially affected newborns before serious symptoms develop.
Yeddi yüzdən çox körpə neonatal skrininq müayinələrə cəlb olunub.
8
According to Ukraine's Ministry of Health, by August 2026:
608,082 newborn screening tests had been conducted.
4,924 cases required further testing.
1,170 cases were confirmed after follow-up testing.
84 confirmed cases involved spinal muscular atrophy.
These figures demonstrate the importance of early genetic diagnosis and the relationship between biotechnology and public healthcare policy.
Moz.gov.ua+1
Legal importance: Early screening supports the right to timely medical intervention. However, a positive screening result is not necessarily a final diagnosis; confirmatory testing and appropriate clinical assessment remain essential.
9. Rare-disease reference centres
Specialised reference centres are important because rare diseases frequently require expertise that may not be available in ordinary healthcare institutions.
Ukraine has developed a network of reference centres under Ministry of Health Order No. 1620 of 7 September 2022.
Their functions include:
Specialist diagnosis.
Genetic counselling.
Treatment planning.
Medical monitoring.
Multidisciplinary consultations.
Professional guidance for regional healthcare institutions.
Coordination of complex treatment.
Reference centres also help improve the consistency of medical decisions and the quality of rare-disease services.
10. Pharmaceutical biotechnology and orphan medicines
Orphan medicines are medicinal products intended for the prevention, diagnosis or treatment of rare diseases.
Biotechnology has contributed to the development of several important treatments, including:
Enzyme replacement therapies.
Recombinant proteins.
Monoclonal antibodies.
Gene therapies.
RNA-based medicines.
Specialised metabolic therapies.
For example:
| Rare disease | Biotechnology-related treatment |
|---|---|
| Spinal muscular atrophy | Nusinersen and gene-based therapies |
| Gaucher disease | Enzyme replacement therapy |
| Fabry disease | Enzyme replacement therapy |
| Haemophilia | Recombinant clotting factors and gene therapies |
| Cystic fibrosis | CFTR-modulator medicines |
| Certain inherited metabolic disorders | Enzyme and specialised metabolic therapies |
Regulatory considerations
Medicines used in Ukraine must comply with applicable pharmaceutical legislation.
The regulatory framework addresses:
Marketing authorisation.
Pharmaceutical quality.
Manufacturing standards.
Clinical evidence.
Safety monitoring.
Pharmacovigilance.
Importation and distribution.
Public procurement.
A medicine being available in another country does not automatically make it legally available for routine use in Ukraine.
Similarly, a medicine's high price does not itself eliminate the legal entitlement to treatment established under Article 53-1.
11. Clinical trials and experimental biotechnology
Clinical trials are important for developing new treatments for rare genetic diseases.
For example, researchers may investigate:
Gene replacement therapy.
CRISPR-based gene editing.
RNA-targeted treatment.
Stem-cell-based therapies.
Recombinant biological products.
Personalised medicine.
However, experimental treatment must comply with applicable Ukrainian clinical-trial and pharmaceutical regulations.
Important legal principles include:
Informed consent: Participants must receive information about the research, risks and possible benefits.
Scientific validity: Clinical trials must have a scientifically justified design.
Ethical supervision: Appropriate ethics review is required.
Patient safety: Researchers must monitor adverse reactions and other safety concerns.
Protection of children: Special safeguards apply when research involves minors.
Experimental treatment should not be confused with an established legal entitlement to approved medicines. The two operate under different regulatory conditions.
12. Genetic data protection and patient confidentiality
Rare-disease patients often provide highly sensitive personal information.
This may include:
DNA sequences.
Family medical histories.
Genetic inheritance patterns.
Prenatal diagnostic results.
Newborn screening results.
Information about hereditary conditions.
Article 32 of the Constitution of Ukraine and the Law of Ukraine on Personal Data Protection provide important privacy protections.
Article 53-1 also provides that medical information concerning rare-disease patients is processed through the electronic healthcare system.
The main legal challenges are:
Unauthorised disclosure of genetic information.
Improper access to electronic medical records.
Unlawful commercial use of genetic information.
Data breaches involving genetic laboratories.
Cross-border transfers of genetic information.
Disputes concerning consent to secondary research use.
A genetic database must be governed by appropriate rules concerning access, confidentiality, lawful processing and data security.
13. Important judicial decisions and case laws
Judicial decisions are particularly important in Ukraine because they explain how statutory rights to rare-disease treatment operate when public authorities fail to provide medicines.
Case 1: M.G. and Y.G. v. Ukraine (Application No. 41714/20)
Important European human-rights case
Court: European Court of Human Rights (ECtHR)
Application: 41714/20
Communicated: 9 February 2021
Published: 15 March 2021
Facts of the case
The first applicant was a child suffering from spinal muscular atrophy (SMA), a serious and progressive rare genetic disease.
His doctors recommended treatment with Nusinersen, marketed as Spinraza.
The medicine was authorised for use in Ukraine in January 2020. However, the authorities did not provide it to the child because of financial limitations.
The child's father approached the healthcare authorities seeking publicly funded treatment.
The Ministry of Health indicated that available state budget funds were insufficient to cover the medicine's cost. The Kyiv City authorities also explained that the local budget could not finance the expensive treatment.
Legal issues
The applicants complained that the government's failure to provide effective treatment violated Article 2 of the European Convention on Human Rights, which protects the right to life.
They relied on Ukraine's domestic legislation, particularly Article 53-1, which provides for continuous and free provision of necessary medicines to rare-disease patients.
Interim measure
On 5 November 2020, the ECtHR indicated under Rule 39 of its Rules of Court that the Ukrainian Government should ensure access to effective medical treatment appropriate to the child's condition, as recommended by the treating doctors.
Legal significance
The case illustrates the connection between:
The right to life.
The state's positive healthcare obligations.
Access to expensive biotechnology medicines.
Children's rights.
Protection of patients suffering from rare diseases.
Important qualification: This is a communicated case and interim-measure decision, not a final ECtHR judgment establishing a definitive violation of Article 2. It should therefore be cited for its facts and interim protection, rather than as a final merits precedent.
HUDOC+1
Case 2: Supreme Court of Ukraine – Acromegaly medicine reimbursement
Supreme Court decision, 2025
Court: Civil Cassation Court within the Supreme Court of Ukraine
Date: 5 March 2025
Case No.: 761/29128/23
Proceedings No.: 61-14855св24
Facts
The claimant suffered from acromegaly, a rare disease requiring continuing treatment with Sandostatin LAR (octreotide).
The patient had to purchase the prescribed medicine using personal funds because the responsible public authority had failed to provide it.
The claimant sought compensation for the expenses incurred.
The first-instance court granted the claim. However, the appellate court overturned that decision, questioning whether the claimant had sufficiently established registration with the authorities and requests for the medicine.
Supreme Court's reasoning
The Supreme Court restored the first-instance decision.
It considered that:
The claimant suffered from a legally recognised rare disease.
The public authority had a statutory obligation to provide the necessary medicine.
Previous final judicial decisions had already established unlawful inaction by the authority.
The patient had incurred expenditure because the public authority failed to fulfil its obligations.
The patient had a legitimate expectation of receiving the necessary medical care.
Legal principle
Where the state unlawfully fails to provide necessary medicines to a rare-disease patient, the patient may claim compensation for the resulting financial loss.
The Court relied on the state's positive healthcare obligations and the Civil Code provisions concerning compensation for damage caused by unlawful acts or omissions of public authorities.
Importance
This is a particularly significant decision for patients who have been forced to purchase expensive medicines privately because of failures in public healthcare provision.
court.gov.ua+1
Case 3: Shevchenkivskyi District Court of Kyiv – Acromegaly and Sandostatin LAR
Court: Shevchenkivskyi District Court of Kyiv
Date: 4 April 2024
Case No.: 761/29128/23
Decision reference: 118575533
Facts
The patient suffered from acromegaly and required regular administration of Sandostatin LAR.
The relevant healthcare authority had failed to provide the prescribed medicine.
The patient had previously brought proceedings seeking recognition of the authority's unlawful inaction and an order requiring it to supply the medicine.
In the earlier proceedings, the court recognised the authority's unlawful failure to provide the medicine.
The patient subsequently sought compensation for expenses incurred in purchasing it.
Legal reasoning
The court considered the statutory obligation to provide free medicines to people with rare diseases.
It also considered the responsibilities of local executive authorities under Ukrainian local-government legislation.
The court found that the patient had suffered financial loss because the medicine had not been provided as legally required.
Importance
The decision demonstrates that rare-disease protection is not merely a general healthcare policy. It can create enforceable legal obligations against responsible public authorities.
справа № 761/29128/23+1
Case 4: Pryonina v. Ukraine (Application No. 63566/00)
Court: European Court of Human Rights
Judgment: 18 July 2006
This case did not concern rare diseases directly. It is relevant to the procedural protection of rare-disease patients.
Legal issue
The ECtHR considered the requirement under Article 6(1) of the European Convention that domestic courts provide adequate reasons for their decisions.
Legal principle
Courts must address the essential arguments raised by parties. Although they are not required to answer every individual argument in detail, their reasoning must be sufficient to demonstrate that the important issues have been considered.
Application to rare-disease litigation
Where a patient claims that a public authority has unlawfully refused life-sustaining treatment, the court should meaningfully examine:
The medical evidence.
The statutory entitlement.
The conduct of the responsible authority.
The evidence of financial loss.
The legal basis for refusing treatment.
This case provides a procedural human-rights principle rather than a direct rare-disease entitlement.
справа № 761/29128/23
14. Legal responsibilities of Ukrainian government authorities
Several public institutions participate in the administration of rare-disease healthcare.
| Authority | Main responsibility |
|---|---|
| Ministry of Health | Policy, disease classification and medical regulation |
| State Expert Centre | Medical standards and regulatory expertise |
| National Health Service of Ukraine | Administration of covered healthcare services |
| Regional healthcare authorities | Regional healthcare organisation |
| Local governments | Local healthcare programmes and funding |
| Healthcare institutions | Diagnosis, treatment and patient-care decisions |
| Medical Procurement of Ukraine | Public procurement of medicines and medical products |
These authorities must operate within their respective legal powers and statutory responsibilities.
15. Public procurement of orphan medicines
One of the most significant problems in rare-disease treatment is the high cost of biotechnology medicines.
Some treatments require repeated administration over a patient's lifetime.
Ukraine uses public procurement to acquire medicines and medical products for rare-disease treatment.
Important procurement considerations include:
Forecasting patient numbers.
Estimating annual treatment requirements.
Assessing medicine prices.
Ensuring product quality.
Maintaining supply continuity.
Monitoring procurement contracts.
Preventing corruption and procurement irregularities.
Ukraine has also used Managed Entry Agreements (MEAs) for certain innovative medicines.
These arrangements can help address uncertainty concerning treatment costs, clinical outcomes and access to expensive medicines.
According to the Ministry of Health's August 2026 report, the 2025 procurement programme included more than UAH 3.8 billion in medicines and medical products for rare-disease patients.
Moz.gov.ua
16. Liability for denial of rare-disease treatment
Public authorities and healthcare institutions may face legal consequences when they unlawfully fail to fulfil their responsibilities.
Possible forms of legal liability include:
A. Civil liability
A patient may seek compensation for financial losses caused by unlawful governmental inaction.
B. Administrative judicial review
A patient may challenge an unlawful decision, refusal or failure to act by a public authority.
C. Professional liability
Healthcare professionals may face consequences where negligence or failure to follow applicable professional standards causes harm.
D. Criminal liability
Criminal responsibility may arise where the elements of a specific criminal offence are established, such as certain forms of professional negligence or unlawful conduct.
E. Human-rights accountability
Serious failures involving life-threatening conditions may raise questions under the European Convention on Human Rights.
Not every interruption in treatment automatically creates liability. The claimant must establish the relevant legal duty, unlawful conduct, damage and required causal connection.
17. Rights of children suffering from rare diseases
Children require particular legal protection because rare genetic diseases frequently become apparent during infancy or early childhood.
The legal framework includes:
The Ukrainian Constitution.
Healthcare legislation.
The Convention on the Rights of the Child.
The right to life and development.
Protection of dignity.
Access to appropriate medical treatment.
Parental or legal-representative participation in medical decisions.
Article 24 of the Convention on the Rights of the Child recognises the child's right to the highest attainable standard of health.
For children with SMA, early diagnosis and timely access to appropriate treatment may be particularly important.
The case of M.G. and Y.G. v. Ukraine demonstrates the importance of judicial protection where the cost of a biotechnology medicine creates a barrier to treatment.
18. International legal framework
Ukraine's rare-disease legislation should also be understood in the context of international human-rights and healthcare standards.
| International instrument | Relevance |
|---|---|
| International Covenant on Economic, Social and Cultural Rights, Article 12 | Right to the highest attainable standard of health |
| Convention on the Rights of the Child, Article 24 | Children's right to healthcare |
| European Convention on Human Rights, Article 2 | Right to life |
| European Convention on Human Rights, Article 8 | Private and family life, including aspects of medical autonomy |
| Convention on the Rights of Persons with Disabilities | Equality, accessibility and healthcare protection |
| Oviedo Convention | Human rights and biomedicine, where applicable to Ukraine |
These instruments support the interpretation of national legislation in matters involving genetic testing, medical treatment, patient dignity and healthcare accessibility.
19. Major legal challenges in Ukraine
Despite the statutory framework, several important difficulties remain.
1. Expensive biotechnology medicines
Advanced gene therapies and biological medicines can create substantial financial pressure on public healthcare budgets.
2. Unequal access to treatment
Patients in rural areas may have less access to specialist genetic laboratories and reference centres.
3. Delayed diagnosis
Some rare diseases are difficult to identify because their symptoms resemble more common medical conditions.
4. Genetic-data confidentiality
The expansion of electronic healthcare systems creates additional responsibilities for protecting genetic and medical information.
5. Procurement interruptions
Delays in public procurement can interrupt the supply of essential medicines.
6. Experimental treatment
The distinction between clinically established treatment and experimental biotechnology can create difficult questions concerning consent, safety and legal responsibility.
7. War-related healthcare disruption
The ongoing effects of the war create additional difficulties involving medicine supply chains, displaced patients, damaged healthcare infrastructure and continuity of treatment.
20. Important developments in 2026
One particularly important development is Ministry of Health Order No. 60 of 15 January 2026, which approved the updated Directory of Rare (Orphan) Diseases.
The directory supports more systematic identification and recording of rare diseases.
It also facilitates improved disease classification, medical documentation and planning of healthcare services.
The introduction of internationally aligned OrphaCode classification into Ukraine's electronic healthcare system is another important development reported in 2026. It helps distinguish rare conditions that may not be sufficiently identifiable through conventional disease classifications.
Moz.gov.ua+1
21. Critical legal analysis
Ukraine's rare-disease framework establishes an important distinction between a patient's legal entitlement and the practical availability of healthcare resources.
Article 53-1 recognises the right to continuous and free provision of necessary medicines and special dietary products. However, the implementation procedure involves medical commissions, budget allocations, procurement and healthcare institutions.
This creates a potential conflict between statutory rights and administrative or financial limitations.
The Supreme Court's decision of 5 March 2025 in Case No. 761/29128/23 is particularly relevant because it confirms that unlawful governmental failure to provide medicines can create an obligation to compensate patients for their resulting expenses.
The ECHR proceedings in M.G. and Y.G. v. Ukraine additionally demonstrate the importance of effective medical protection for children suffering from serious genetic diseases.
From a biotechnology-law perspective, Ukraine faces five important regulatory priorities:
Expanding access to advanced genetic diagnosis.
Establishing reliable and secure rare-disease databases.
Improving access to innovative orphan medicines.
Strengthening clinical-trial and biotechnology oversight.
Ensuring effective remedies when public healthcare obligations are breached.
A future comprehensive rare-disease framework could also improve regulation of gene therapy, genomic medicine, personalised treatment and cross-border access to specialised medicines.
22. Conclusion
Biotechnology Rare Disease Law in Ukraine combines constitutional healthcare rights, pharmaceutical regulation, genetic diagnostics, public procurement, medical-data protection and human-rights principles.
The principal statutory foundation is Article 53-1 of the Law on the Fundamentals of Health Legislation, introduced through Law No. 1213-VII of 15 April 2014.
The legal framework requires public authorities to organise appropriate healthcare and provides for continuous and free access to necessary medicines and special dietary products for eligible rare-disease patients.
The judicial decisions discussed above demonstrate that these obligations can have practical legal consequences. In particular, the Supreme Court's 2025 ruling establishes an important basis for compensation when patients have to purchase necessary medicines because of unlawful governmental inaction.
Ultimately, the development of biotechnology in Ukraine must be accompanied by effective legal protection, equitable access to treatment, genetic privacy and accountability of public healthcare institutions.
23. Important legal references and research sources
For further academic and legal research:
Law of Ukraine on the Fundamentals of Health Legislation.
Law No. 1213-VII – Rare Disease Legislation.
Cabinet Resolution No. 160 of 2015.
Ministry of Health Order No. 60 of 2026.
M.G. and Y.G. v. Ukraine – ECtHR.
Supreme Court decision of 5 March 2025.
Shevchenkivskyi District Court decision – Case No. 761/29128/23.
Ukraine Ministry of Health – Newborn screening report, August 2026.
Academic note: The 2021–2026 government strategy is a time-limited policy framework, not a permanent statute. Also, the communicated ECtHR case should not be described as a final judgment. The legal analysis above distinguishes binding legislation, judicial holdings and illustrative proceedings.
This material is suitable as a foundation for a legal research paper, biotechnology-law assignment or comparative study of Ukrainian healthcare regulation.

comments